Boston Scientific Co. (NYSE:BSX) Shares Purchased by Avantax Advisory Services Inc.

Avantax Advisory Services Inc. increased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 25.0% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 36,416 shares of the medical equipment provider's stock after buying an additional 7,282 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Boston Scientific were worth $3,253,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. State Street Corp grew its stake in shares of Boston Scientific by 2.3% in the third quarter. State Street Corp now owns 62,846,328 shares of the medical equipment provider's stock worth $5,266,522,000 after acquiring an additional 1,389,172 shares during the period. Wellington Management Group LLP raised its stake in Boston Scientific by 2.2% during the 3rd quarter. Wellington Management Group LLP now owns 32,820,828 shares of the medical equipment provider's stock valued at $2,750,385,000 after buying an additional 718,515 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Boston Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 29,584,841 shares of the medical equipment provider's stock worth $2,469,607,000 after buying an additional 480,729 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Boston Scientific by 5.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,475,031 shares of the medical equipment provider's stock worth $756,990,000 after acquiring an additional 456,654 shares during the period. Finally, Fisher Asset Management LLC increased its position in Boston Scientific by 21.6% during the fourth quarter. Fisher Asset Management LLC now owns 5,800,912 shares of the medical equipment provider's stock valued at $518,138,000 after acquiring an additional 1,028,977 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Remove Ads

Boston Scientific Stock Up 1.7 %

NYSE:BSX traded up $1.66 during mid-day trading on Monday, reaching $98.82. The company's stock had a trading volume of 2,145,906 shares, compared to its average volume of 5,730,739. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 1 year low of $66.16 and a 1 year high of $107.17. The stock has a fifty day moving average of $101.05 and a 200-day moving average of $91.84. The firm has a market capitalization of $145.83 billion, a PE ratio of 79.05, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. Equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Royal Bank of Canada upped their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. StockNews.com downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. UBS Group boosted their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Finally, Morgan Stanley raised their price target on Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $108.91.

Insider Activity

In related news, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the transaction, the executive vice president now directly owns 35,319 shares of the company's stock, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Daniel J. Brennan sold 67,333 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the sale, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. This represents a 22.97 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 137,302 shares of company stock worth $14,319,269. Corporate insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.